AU2021323253A1 - Heterocyclic GLP-1 agonists - Google Patents

Heterocyclic GLP-1 agonists Download PDF

Info

Publication number
AU2021323253A1
AU2021323253A1 AU2021323253A AU2021323253A AU2021323253A1 AU 2021323253 A1 AU2021323253 A1 AU 2021323253A1 AU 2021323253 A AU2021323253 A AU 2021323253A AU 2021323253 A AU2021323253 A AU 2021323253A AU 2021323253 A1 AU2021323253 A1 AU 2021323253A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
ring
group
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021323253A
Other languages
English (en)
Other versions
AU2021323253A8 (en
Inventor
Andrew Jennings
Hui Lei
Xichen Lin
Qinghua Meng
Haizhen ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gasherbrum Bio Inc
Original Assignee
Gasherbrum Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gasherbrum Bio Inc filed Critical Gasherbrum Bio Inc
Publication of AU2021323253A1 publication Critical patent/AU2021323253A1/en
Publication of AU2021323253A8 publication Critical patent/AU2021323253A8/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021323253A 2020-08-06 2021-08-06 Heterocyclic GLP-1 agonists Pending AU2021323253A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/107437 2020-08-06
CN2020107437 2020-08-06
CNPCT/CN2021/073958 2021-01-27
CN2021073958 2021-01-27
PCT/CN2021/111193 WO2022028572A1 (en) 2020-08-06 2021-08-06 Heterocyclic glp-1 agonists

Publications (2)

Publication Number Publication Date
AU2021323253A1 true AU2021323253A1 (en) 2023-02-23
AU2021323253A8 AU2021323253A8 (en) 2023-03-16

Family

ID=80117080

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021323253A Pending AU2021323253A1 (en) 2020-08-06 2021-08-06 Heterocyclic GLP-1 agonists

Country Status (23)

Country Link
US (3) US11897851B2 (https=)
EP (1) EP4192831B1 (https=)
JP (1) JP2023537501A (https=)
KR (1) KR20230053620A (https=)
CN (1) CN116323599A (https=)
AU (1) AU2021323253A1 (https=)
CA (1) CA3190163A1 (https=)
CL (2) CL2023000374A1 (https=)
CO (1) CO2023001263A2 (https=)
CR (1) CR20230066A (https=)
DK (1) DK4192831T3 (https=)
DO (1) DOP2023000023A (https=)
FI (1) FI4192831T3 (https=)
HR (1) HRP20251653T1 (https=)
IL (1) IL300155A (https=)
LT (1) LT4192831T (https=)
MX (1) MX2023001311A (https=)
PE (1) PE20231181A1 (https=)
PL (1) PL4192831T3 (https=)
PT (1) PT4192831T (https=)
SI (1) SI4192831T1 (https=)
TW (1) TW202220973A (https=)
WO (1) WO2022028572A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
EP4204415A4 (en) 2020-08-28 2025-03-26 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
JP7772778B2 (ja) 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
CN117222644A (zh) * 2021-04-12 2023-12-12 诺华股份有限公司 2-((4-((S)-2-(4-氯-2-氟苯基)-2-甲基苯并[d][1,3]二氧戊环-4-基)哌啶-1-基)甲基)-1-(((S)-氧杂环丁烷-2-基)甲基)-1H-咪唑衍生物作为GLP1受体激活剂治疗肥胖症
WO2022219495A1 (en) * 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
CA3215916A1 (en) * 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2023029380A1 (zh) 2021-08-30 2023-03-09 杭州德睿智药科技有限公司 作为glp1r激动剂的新型芳醚取代杂环类化合物
US20240374587A1 (en) 2021-09-08 2024-11-14 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
MX2024004131A (es) 2021-10-05 2024-04-22 Astrazeneca Ab Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1.
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
US20250115612A1 (en) 2021-10-05 2025-04-10 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
JPWO2023106310A1 (https=) * 2021-12-07 2023-06-15
WO2023111144A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250042882A1 (en) 2021-12-16 2025-02-06 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
JP2025506474A (ja) * 2022-02-09 2025-03-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
US20250177362A1 (en) * 2022-02-09 2025-06-05 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4476212A1 (en) * 2022-02-10 2024-12-18 Novartis AG 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
EP4592285A1 (en) 2022-09-22 2025-07-30 Shionogi & Co., Ltd. Fused ring compound having glp-1 receptor agonist effect
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
KR20250085816A (ko) 2022-11-16 2025-06-12 일라이 릴리 앤드 캄파니 글루카곤-유사 펩티드 1 수용체 효능제
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
WO2025007843A1 (zh) * 2023-07-03 2025-01-09 德睿智药(苏州)新药研发有限公司 作为glp1r激动剂的新型前药化合物或稠环化合物
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2025222008A1 (en) * 2024-04-19 2025-10-23 Eli Lilly And Company Glucagon receptor agonists and their use as therapies

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6628343B1 (en) 1997-05-23 2003-09-30 Sony Corporation Television signal reception circuit, automatic phase shift control circuit and equal amplitude addition circuit
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
KR101025633B1 (ko) 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
US7777051B2 (en) 2003-05-13 2010-08-17 Icagen, Inc. Asymmetric benzimidazoles and related compounds as potassium channel modulators
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US20080051387A1 (en) 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
WO2008012623A1 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
KR20090130345A (ko) 2007-05-04 2009-12-22 아이알엠 엘엘씨 Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 화합물 및 조성물
WO2008153701A1 (en) 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
CL2009001214A1 (es) 2008-05-19 2010-12-31 Schering Corp Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos
WO2010065674A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8420655B2 (en) 2009-12-04 2013-04-16 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
JP6126097B2 (ja) 2011-09-06 2017-05-10 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体
CN109867630A (zh) 2013-06-11 2019-06-11 赛尔基因第二国际有限公司 新型glp-1受体调节剂
CA2955836C (en) 2014-07-25 2023-02-14 Celgene International Ii Sarl Glp-1 receptor modulators
SG11201805586SA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
CN108430998B (zh) 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CN108017636A (zh) 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
KR102314286B1 (ko) 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
US11136324B2 (en) 2017-03-03 2021-10-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
DK3806855T5 (da) 2018-06-15 2023-05-22 Pfizer GLP-1-receptoragonister og anvendelser deraf
US11254660B2 (en) 2018-08-31 2022-02-22 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
MA54555A (fr) 2018-11-22 2021-09-29 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
CN113365637A (zh) 2018-12-05 2021-09-07 维京治疗公司 用于治疗肝部病症的组合物和方法
EP3953344A4 (en) 2019-04-12 2023-08-09 Qilu Regor Therapeutics Inc. GLP-IR AGONISTS AND THEIR USES
WO2020234726A1 (en) 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2021018023A1 (zh) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
EP4048664A1 (en) 2019-10-25 2022-08-31 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2021096284A1 (ko) 2019-11-15 2021-05-20 일동제약(주) Glp-1 수용체 작용제 및 이의 용도
CN114761395B (zh) 2019-12-02 2024-11-15 现代药品株式会社 Glp-1受体激动剂
ES3016132T3 (en) 2020-01-29 2025-05-08 Gilead Sciences Inc Glp-1r modulating compounds
JP7836762B2 (ja) 2020-02-13 2026-03-27 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
IL296336A (en) 2020-03-18 2022-11-01 Lg Chemical Ltd Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
CN113493447B (zh) 2020-04-03 2024-06-11 轩竹(北京)医药科技有限公司 Glp-1受体激动剂
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
MX2022015026A (es) 2020-06-04 2023-01-04 Hangzhou Sciwind Biosciences Co Ltd Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo.
CN115697338B (zh) 2020-06-10 2024-08-09 东宝紫星(杭州)生物医药有限公司 甲基取代的苯并二噁唑类化合物及其应用
CN117645601A (zh) 2020-06-10 2024-03-05 重庆康丁医药技术有限公司 一种具有心血管益处的glp-1小分子
CN113801136B (zh) 2020-06-16 2023-04-07 江苏恒瑞医药股份有限公司 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN115916772B (zh) 2020-06-19 2025-01-14 江苏恒瑞医药股份有限公司 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN113816948B (zh) 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN113831337B (zh) 2020-06-24 2023-03-24 广州市恒诺康医药科技有限公司 Glp-1受体激动剂及其药物组合物和用途
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
WO2022031994A1 (en) 2020-08-06 2022-02-10 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
CA3192601A1 (en) 2020-08-21 2022-02-24 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
EP4204415A4 (en) 2020-08-28 2025-03-26 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
CA3188891A1 (en) 2020-09-01 2022-01-13 Fanglong Yang Fused imidazole derivative, preparation method therefor, and medical use thereof
EP4211133A4 (en) 2020-09-07 2024-11-27 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
WO2022068772A1 (zh) 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
WO2022078152A1 (zh) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
EP4229050A4 (en) 2020-10-13 2024-12-11 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20240083886A1 (en) 2020-10-13 2024-03-14 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
MX2023006186A (es) 2020-11-27 2023-08-07 Shenzhen Salubris Pharm Co Ltd Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo.
CN114591296A (zh) 2020-12-02 2022-06-07 海思科医药集团股份有限公司 一种glp-1r激动剂及其在医药上的应用
CN114591308B (zh) 2020-12-03 2024-03-08 苏州闻泰医药科技有限公司 一类glp-1r受体激动剂化合物及其用途
CN114634510B (zh) 2020-12-16 2025-11-04 杭州中美华东制药有限公司 咪唑并吡啶衍生物及其用途
WO2022135572A1 (zh) 2020-12-25 2022-06-30 四川海思科制药有限公司 一种五并五元环衍生物及其在医药上的应用
CN114763352A (zh) 2021-01-15 2022-07-19 海思科医药集团股份有限公司 一种glp-1受体激动剂及其在医药上的应用
CR20230330A (es) 2021-01-28 2023-11-15 Carmot Therapeutics Inc Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso
CN114907351A (zh) 2021-02-07 2022-08-16 杭州中美华东制药有限公司 三环类glp-1受体激动剂及其用途
EP4304712A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
US20240208952A1 (en) 2021-03-22 2024-06-27 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Thiophene glp-1 receptor agonist and use thereof
JP7772778B2 (ja) 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
CN117222631A (zh) 2021-03-24 2023-12-12 诚益生物(美国)公司 苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-苯基-、苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-杂芳基-或苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-哌啶基-甲基-氧杂环丁烷基甲基-1h-苯并[d]咪唑-甲酸衍生物及其使用方法
WO2022216094A1 (ko) 2021-04-08 2022-10-13 주식회사 엘지화학 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
WO2022219495A1 (en) * 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
CN117177970A (zh) * 2021-04-30 2023-12-05 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用
CN115594669B (zh) 2021-07-09 2024-11-05 深圳信立泰药业股份有限公司 一种并环类衍生物及其制备方法和医药用途
CN113480534B (zh) 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
EP4469444A4 (en) 2022-01-24 2026-01-07 Gasherbrum Bio Inc GLP-1 HETEROCYCLIC AGONISTS
US20250177362A1 (en) 2022-02-09 2025-06-05 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2025506474A (ja) 2022-02-09 2025-03-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
US20250206757A1 (en) 2022-03-21 2025-06-26 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN114716423A (zh) 2022-05-20 2022-07-08 中国科学院上海药物研究所 5,6-二氢-1,2,4-三嗪类化合物及其作为glp-1受体激动剂的药学用途

Also Published As

Publication number Publication date
CO2023001263A2 (es) 2023-05-19
JP2023537501A (ja) 2023-09-01
FI4192831T3 (fi) 2025-12-31
IL300155A (en) 2023-03-01
FI4192831T9 (fi) 2026-01-15
US20240376061A1 (en) 2024-11-14
CN116323599A (zh) 2023-06-23
MX2023001311A (es) 2023-04-18
CA3190163A1 (en) 2022-02-10
DK4192831T3 (da) 2026-01-12
TW202220973A (zh) 2022-06-01
KR20230053620A (ko) 2023-04-21
AU2021323253A8 (en) 2023-03-16
US20230192633A1 (en) 2023-06-22
HRP20251653T1 (hr) 2026-02-13
EP4192831B1 (en) 2025-10-22
EP4192831A1 (en) 2023-06-14
SI4192831T1 (sl) 2026-03-31
DOP2023000023A (es) 2023-02-28
PE20231181A1 (es) 2023-08-11
CL2023000374A1 (es) 2023-11-03
US20260055069A1 (en) 2026-02-26
PT4192831T (pt) 2026-01-12
PL4192831T3 (pl) 2026-04-27
WO2022028572A1 (en) 2022-02-10
CR20230066A (es) 2023-05-29
CL2023001924A1 (es) 2024-02-16
US12528781B2 (en) 2026-01-20
US11897851B2 (en) 2024-02-13
LT4192831T (lt) 2026-02-10
EP4192831A4 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
US12528781B2 (en) Heterocyclic GLP-1 agonists
US12221442B2 (en) Heterocyclic GLP-1 agonists
EP4229049A1 (en) Heterocyclic glp-1 agonists
US20230165846A1 (en) Heterocyclic glp-1 agonists
WO2023169456A1 (en) Heterocyclic glp-1 agonists
WO2023016546A1 (en) Heterocyclic glp-1 agonists
EP4211133A1 (en) Heterocyclic glp-1 agonists
WO2022052958A1 (en) Heterocyclic glp-1 agonists
EP4476213A1 (en) Heterocyclic glp-1 agonists
EP4476216A1 (en) Heterocyclic glp-1 agonists
WO2023198140A1 (en) Heterocyclic glp-1 agonists
EP4496797A1 (en) 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 57 , NO 7 , PAGE(S) 1064 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME GASHERBRUM BIO, INC. APPLICATION NO.2021323253, UNDER INID (72) ADD CO-INVENTOR MENG, QINGHUA